Arcutis Biotherapeutics Officer Files Intent to Sell $417K in Stock
Arcutis Biotherapeutics, Inc.
Subscribe to track ARQT
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Arcutis Biotherapeutics Officer Files Intent to Sell $417K in Stock
Company: Arcutis Biotherapeutics, Inc. (ARQT) Form: 144 | Filed: 2025-11-06 Significance: Low
Insider: Patrick Burnett Title: Not Specified | Relationship: Officer
Transaction (Proposed): • Type: Sale • Shares: 17,250 • Approx. Value: $417,145 • Approx. Price: $24.18
Key Insight: An officer has filed a notice of a proposed sale of common stock. The transaction size is minor, representing approximately 0.014% of the company's market capitalization.
Market Context: This is a routine filing of intent to sell, and the value is not material relative to the company's $2.94 billion market cap. The sale is planned under a 10b5-1 trading plan adopted on December 12, 2024.
Comprehensive Analysis
SEC Filing Analysis: Arcutis Biotherapeutics, Inc. (ARQT)
Executive Summary
- Trading Significance: Low
- Key Takeaway: An officer of Arcutis Biotherapeutics has filed a Form 144, indicating a proposed sale of 17,250 shares valued at approximately $417,145.
- Market Impact: The transaction is considered immaterial and is unlikely to have a significant impact on the stock price due to its small size relative to the company's market capitalization and shares outstanding.
Company Information
| Field | Value |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. |
| Ticker Symbol | ARQT |
| CIK | 0001787306 |
| Industry | PHARMACEUTICAL PREPARATIONS |
Insider Information
| Field | Value |
|---|---|
| Name | Patrick Burnett |
| CIK | 0001741987 |
| Title/Position | Not Specified |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 |
| Transaction Date | 2025-11-06 (Approximate Sale Date) |
| Transaction Code | S (Proposed Sale) |
| Security Type | Common Stock |
| Shares Involved | 17,250 |
| Price Per Share | $24.18 (Approximate) |
| Total Value | $417,145 |
| Shares Owned After | Not Specified |
| Ownership Type | Not Specified |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $417,145 |
| % of Market Cap | 0.014% |
| Shares Transacted | 17,250 |
| % of Shares Outstanding | 0.014% |
| Post-Transaction Ownership | Not Specified |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The proposed sale of $417,145 is a negligible fraction of Arcutis Biotherapeutics' $2.94 billion market capitalization.
- Transaction Significance: The transaction is not significant, representing less than 0.1% of both market cap and shares outstanding, falling well below the thresholds for moderate or high significance.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: A Form 144 filing for a sale of this small size is a routine disclosure for corporate insiders and does not typically influence market sentiment or stock price.
Volume & Sentiment
- Expected Volume Impact: Minimal. The number of shares is too small to materially affect daily trading volume.
- Sentiment Indicator: Neutral. The filing is informational and does not signal a change in the insider's outlook on the company.
Additional Context
Transaction Notes
- Special Circumstances: The filing indicates the sale is to be made under a pre-arranged 10b5-1 trading plan adopted on December 12, 2024. This suggests the sale was planned in advance and is not based on recent non-public information.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.